TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
Study identifier:D5180C00034
ClinicalTrials.gov identifier:NCT05729711
EudraCT identifier:N/A
CTIS identifier:N/A
Recruiting
Official Title
TEZSPIRE Subcutaneous Injection 210mg Specific use-results study (Long term) in patients with Bronchial asthma.
Medical condition
Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy)
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Estimated Enrollment
400
Study type
Observational
Age
n/a - n/a
Date
Study Start Date: 04 Apr 2023
Estimated Primary Completion Date: 16 Nov 2029
Estimated Study Completion Date: 16 Nov 2029
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Apr 2024 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
Sort by status
- All Statuses
- Recruiting
- Not yet recruiting
- Recruiting complete
- Completed
- Withdrawn
- Other
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Toshimitsu Tokimoto
AstraZeneca KK
